Savvy Updates, 6/6/22: Abbott Libre 3 & Lingo, Diabeloop $$, iLet Bionic Pancreas Trial, Apple Watch BG Monitoring, Medtronic Struggles, Diabetes & Long Covid, Dexcom Denies Rumors, Pharmacy Benefit Managers Cost Consumers

US FDA approves Abbott’s FreeStyle Libre 3 system for diabetic patients was reported by, 1 June 2022.  

The US Food and Drug Administration (FDA) has granted clearance to Abbott’s next-generation FreeStyle Libre 3 system for use by diabetic patients aged four years and above.

The new device, which includes a continuous glucose monitoring (CGM) sensor, recorded a 7.9% overall mean absolute relative difference (MARD) and is claimed to be the most accurate 14-day CGM system.  FreeStyle Libre 3 sends glucose readings directly from the glucose sensor, which is said to be the smallest and thinnest in the world, to a smartphone every minute.  The CGM system also has strong Bluetooth integration, with a range of up to 33ft, which represents a 50% increase over other CGMs.

Leave a Reply

Your email address will not be published.